
Keywords: BRS; bioresorbable scaffold; DAPT; dual antiplatelet therapy; MACE; major adverse cardiac event; ST; stent or scaffold thrombosis; TAT; triple antithrombotic therapy; TLF; target lesion failure; TLR; target lesion revascularization; TVF; target vessel fai